IDT biologics
| IDT biologics
|
|
|---|---|
 |
|
| legal form | GmbH |
| founding | July 1, 1921 |
| Seat | Dessau-Roßlau , Germany |
| management | Jürgen Betzing, Boris Trautmann, Christian Wirth |
| Number of employees | 1,600 (2018) |
| sales | 205 million euros (2018) |
| Branch | Pharmaceutical Industry |
| Website | idt-biologika.de |
| Status: 2018 | |
The IDT Biologics is a German company the biopharmaceutical based in Dessau . It develops and manufactures biotechnology produced vaccines and pharmaceuticals . The company is part of the Klocke Group .
Company profile
In 2018, the company employed around 1,600 people and generated sales of 205 million euros. The company invests up to 20 percent of annual sales in research and development of its own products. The company's locations in Germany are the BioPharmaPark in Dessau-Roßlau and the Greifswald district of Riems. IDT operates sales offices in the USA, Denmark, the Netherlands, France and Spain, the focus of which is on the animal health business. IDT Biologika is active in the animal health, vaccines, pharmaceuticals and quality control businesses.
- Animal health develops and produces animal vaccines from its own research for the prophylaxis and therapy of animal diseases. 50 veterinary products for livestock and hobby animals are used in the veterinary practice.
- Vaccines develops technologies for viral and bacterial vaccines for prophylactic and therapeutic applications, such as: B. against malaria and HIV as well as tumor diseases.
- The pharmaceuticals division develops and manufactures liquid dosage forms ( parenterals ) in syringes, vials, ampoules and bottles. The business area also specializes in lyophilization .
- Quality control includes analytical methods for testing vaccines and pharmaceuticals based on our own research, development and production.
The company has been successfully inspected by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
history
.jpg)
.jpg)
Background: Bacteriological, Serum and Hygiene Institute in Dessau
On July 1, 1921 Friedrich Richter founded the Bacteriological Institute of the Anhalt Districts in Dessau. Among other things, the institute devoted itself to the detection and diagnosis of tuberculosis in humans and animals. On April 1, 1924, Ludwig Wolters took over the management of the institute. The institute developed into a center for health protection by 1945. The first beginnings in the manufacture of vaccines, serums and pesticides were made. The production of immune sera against the erysipeloid began.
The Anhaltische Serum-Institut GmbH Dessau (ASID) was founded on May 31, 1930 under the direction of Wolters and Herbert Hoffmann. In addition to the production of serums and vaccines to combat animal diseases, the range of services also included bacterial pest control and research into and control of sheep frenzy.
The Hygiene Institute was converted into a public corporation on November 3, 1933. The institute was now subordinate to the Anhalt State Ministry. He was now responsible for the sovereign tasks of public health care and the safeguarding of livestock under the laws of the Reich and the Land. The society was granted the status of a scientific research institute on April 9, 1947.
History during the GDR: VEB Kombinat Veterinärimpfstoffe Dessau
The institute was renamed VEB Serum-Werk Dessau on January 1, 1951 and was considered an important company in the GDR for the supply of vaccines and drugs for veterinary and human vaccines. The serum plant in Dessau was assigned directly to the Ministry of Agriculture and Forestry on July 1, 1953, following a resolution by the GDR Council of Ministers (1950–1954) . On January 1, 1954, the production-oriented VEB Serum plant in Dessau became the scientifically oriented research institute for vaccines in Dessau. The institute was commissioned to provide vaccines for all major animal infectious diseases for the GDR and also for export. In the field of human medicine, preparations were new or further developed, e.g. B. tuberculin and serums against tetanus and diphtheria . On January 23, 1973, Wilfried Heinicke, former head of the veterinary department in the Ministry of Agriculture, Forestry and Food Management, became the new director of the institute. While the Research Institute for Vaccines from 1954 to 1973 was mainly devoted to application-oriented basic research and the development of vaccines, serums and diagnostics for veterinary and human medicine, research into the immunological basis of bacterial animal diseases, applied vaccine research and also Research into vaccine production technology intensified. In 1985 the Institute for Vaccines in Dessau had nearly 1,500 employees.
The VEB Kombinat Veterinärimpfstoffe Dessau was founded on January 1, 1985, which was directly subordinate to the GDR Ministry of Agriculture. The combine consisted of three facilities: the Dessau-Tornau vaccine plant with its Institute for Vaccines Dessau, which is integrated as a research center into the main plant, and the Tornau plant that is currently under construction; the VEB Friedrich-Loeffler-Institut Insel Riems, a combined company with a focus on the production of vaccines against viral diseases in animals - and the state-owned Gut Seehausen / Plaußig. From 1988 onwards, the Dessau Institute for Vaccines focused on veterinary diagnostics as part of a development program and prepared for industrial diagnostics production. The development of virus vaccines also continued. On the agenda were, for example, live vaccines against duck plague and goose influenza or vaccines against viral infections of fur animals, canids and felids. As an in-house development, a live rabies vaccine was approved.
By resolution of the GDR Council of Ministers, the dissolution or unbundling of the Dessau Veterinary Vaccines Combine began on May 1, 1990. As a result, the Dessau vaccine plant and the other two combine companies, the VEB Friedrich-Loeffler-Institut Insel Riems and the VEG Seehausen-Plaussig, were again subordinated to the Academy of Agricultural Sciences Berlin on May 1, 1990 and later transferred to the research landscape of the Federal Republic.
Reorganization and privatization: Impfstoffwerk Dessau-Tornau GmbH
On July 24, 1990, the Dessau-Tornau vaccine plant was entered in the commercial register as “GmbH under construction”. The Treuhandanstalt confirmed Heinz Hofmann as managing director of the company operating under the name “Impfstoffwerk Dessau-Tornau GmbH” from October 1990. The first wave of layoffs, which began around the same time as monetary, economic and social union, on July 1, 1990, affected around 800 employees; after further mass layoffs, only around 125 employees remained in the company. Due to the collaboration, Hartmut Klocke submitted the purchase application for the Dessau-Tornau vaccine plant to the Treuhandanstalt Halle in June 1992. On March 1, 1993, the Impfstoffwerk Dessau-Tornau GmbH was privatized as a previously not economically independent part of the Impfstoffwerk Dessau-Tornau Beteiligungs- und Verwaltungsgesellschaft mbH.
With 16 nationwide approvals and 12 approval procedures, the development of the West German market began in 1994, when the company again employed 172 people. The main products produced were Rabifox, Salmonella vaccines, hormone and serum preparations as well as mushroom vaccines. Another four approvals increased the number of approved biologics to 29 in 1997. The niche strategy with the focus on cytostatics , narcotics and X-ray contrast media as well as prefabricated glass syringes, teat applicators and technology for lyophilized ampoules increased sales in 1997 to DM 41 million. With the completion and commissioning of the new vaccine plant ("IDT 2000"), the basis for the manufacture of our own vaccines and contract manufacturing for third parties was laid. At the turn of the millennium, 249 employees were again working in Dessau-Tornau. The implementation of a large-scale manufacturing process for live smallpox vaccines was successful. A secret US dispatch sees the smallpox vaccines as the reason that IDT Biologika is an essential facility for the USA.
From 2004 investments were made in the new construction of the laboratory building for research and development, in a warehouse with a barcode-supported warehouse management system and in a new freeze-drying system. In 2005 the new construction of the virus production began, in 2006 the vaccine production was expanded and a packaging line for smallpox packaging was put into operation. The company name was changed in October 2007. The Impfstoffwerk Dessau-Tornau GmbH became IDT Biologika GmbH. In 2010, a swine influenza animal vaccine with all three current subtypes was launched.
IDT continued the expansion of the site in Dessau with a new building for vaccine production, which was inaugurated in 2013. In addition, the infrastructure was expanded to include a new warehouse, a waste collection center and a combined heat and power plant.
In 2013, IDT Biologika acquired the production and research facilities of Riemser Pharma GmbH in Riems - City of Greifswald. There took IDT Biologics (Riems) in November 2013 her work. In 2015, the expansion of the new location began with the laying of the foundation stone for a new research building, with an investment volume of € 10 million and the modernization of production and logistics.
On the basis of its own new products such as the vaccine against the swine edema disease, IDT Biologika expanded its sales activities in the animal health segment to Europe and founded subsidiaries in Denmark, the Netherlands, France and Spain.
Since June 2015, IDT Corporation has had a manufacturing facility for clinical test samples in Rockville, Maryland.
On September 1, 2015, IDT Biologika will take over Gallant Custom Laboratories in Cambridge, Ontario, Canada. Gallant Custom Laboratories is the only Canadian licensed company to manufacture inventory viral and bacterial vaccines.
literature
- Wolfgang Boden: Review of the history of IDT Biologika GmbH by Julian Azar
Web links
- IDT website
- The company records of the "Alfred Freyberg Foundation / Anhaltische Serum-Institut GmbH" and the "VEB Impfstoffwerk Dessau" are in the Dessau department of the Saxony-Anhalt State Archives under [1] and [2]
Individual evidence
- ↑ Who we are - IDT Biologika. IDT Biologika, accessed June 4, 2020 .
- ↑ WikiLeaks
- ↑ New research complex inaugurated . IDT Biologika website. Retrieved June 1, 2015.
- ↑ New warehouse and packaging . IDT Biologika website. Retrieved June 1, 2015.
- ↑ History: 2004-2006 ( Memento of the original from March 7, 2016 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. . IDT Biologika Animal Health website. Retrieved June 1, 2015.
- ↑ IDT between yesterday and today . IDT Biologika website. Retrieved June 1, 2015.
- ↑ Triple Influenza Vaccine . Top agrar online website. Retrieved June 1, 2015.
- ↑ Pharmaceutical manufacturer expands facilities . Volksstimme website. Retrieved June 1, 2015.
- ↑ IDT Biologika puts new combined heat and power plant into operation . Mitteldeutsche Zeitung website. Retrieved June 1, 2015.
- ↑ Riemser Tierarzneimittel has a new owner . Website of the Norddeutscher Rundfunk. Retrieved June 5, 2015.
- ↑ IDT Biologika builds new research building: Merkel expects. . Focus online website. Retrieved June 7, 2015.
- ↑ IDT Biologika expands its location in Mecklenburg-Western Pomerania . Website of the Ministry of Economy, Building and Tourism Mecklenburg-Western Pomerania. Retrieved June 5, 2015.
- ↑ Worldwide hope for piglet breeders ( page no longer available , search in web archives ) Info: The link was automatically marked as defective. Please check the link according to the instructions and then remove this notice. . Website of the metropolitan region of Central Germany. Retrieved June 7, 2015.
- ↑ IDT Biologika: From checked history to leading animal health 'Mittelstand' . Informa Agra website. Retrieved June 8, 2015.
- ↑ IDT Biologika expands into the USA . Mitteldeutsche Zeitung website. Retrieved September 30, 2015.
- ↑ IDT Biologika acquires company in Canada . Mitteldeutsche Zeitung website. Retrieved September 30, 2015.
